ROS-responsive "smart" polymeric conjugate: Synthesis, characterization and proof-of-concept study.


Journal

International journal of pharmaceutics
ISSN: 1873-3476
Titre abrégé: Int J Pharm
Pays: Netherlands
ID NLM: 7804127

Informations de publication

Date de publication:
30 Oct 2019
Historique:
received: 04 06 2019
revised: 26 08 2019
accepted: 30 08 2019
pubmed: 4 9 2019
medline: 13 2 2020
entrez: 4 9 2019
Statut: ppublish

Résumé

New approaches integrating stimuli-responsive linkers into prodrugs are currently emerging. These "smart" prodrugs can enhance the effectivity of conventional prodrugs with promising clinical applicability. Oxidative stress is central to several diseases, including cancer. Therefore, the design of prodrugs that respond to ROS stimulus, allowing a selective drug release in this condition, is fairly encouraging. Aiming to investigate the ROS-responsiveness of prodrugs containing the ROS-cleavable moiety, Thioketal (TK), we performed proof-of-concept studies by synthesizing ROS-responsive conjugate, namely mPEG-TK-Cy5, through exploiting Cy5 fluorescent dye. We demonstrated that, differently to non-ROS-responsive control conjugate (mPEG-Cy5), mPEG-TK-Cy5 shows a selective release of Cy5 in response to ROS in both, ROS-simulated conditions and in vitro on glioblastoma cells. Our results confirm the applicability of TK-technology in the design of ROS-responsive prodrugs, which constitutes a promising approach in cancer treatment. The translatability of this technology for other diseases treatment makes this a highly relevant and promising approach.

Identifiants

pubmed: 31479731
pii: S0378-5173(19)30700-8
doi: 10.1016/j.ijpharm.2019.118655
pii:
doi:

Substances chimiques

Polymers 0
Prodrugs 0
Reactive Oxygen Species 0
Polyethylene Glycols 3WJQ0SDW1A

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

118655

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Natalia Oddone (N)

Nanotech Lab TeFarTI Group, University of Modena and Reggio Emilia, Department of Life Sciences, Modena, Italy.

Francesca Pederzoli (F)

Department of Biological Sciences, University of Limerick, Limerick, Ireland.

Jason T Duskey (JT)

Nanotech Lab TeFarTI Group, University of Modena and Reggio Emilia, Department of Life Sciences, Modena, Italy.

Chiara A De Benedictis (CA)

Department of Biological Sciences, University of Limerick, Limerick, Ireland; Bernal Institute, University of Limerick, Limerick, Ireland.

Andreas M Grabrucker (AM)

Department of Biological Sciences, University of Limerick, Limerick, Ireland; Bernal Institute, University of Limerick, Limerick, Ireland; Health Research Institute (HRI), University of Limerick, Limerick, Ireland.

Flavio Forni (F)

Nanotech Lab TeFarTI Group, University of Modena and Reggio Emilia, Department of Life Sciences, Modena, Italy.

Maria Angela Vandelli (M)

Nanotech Lab TeFarTI Group, University of Modena and Reggio Emilia, Department of Life Sciences, Modena, Italy.

Barbara Ruozi (B)

Nanotech Lab TeFarTI Group, University of Modena and Reggio Emilia, Department of Life Sciences, Modena, Italy.

Giovanni Tosi (G)

Nanotech Lab TeFarTI Group, University of Modena and Reggio Emilia, Department of Life Sciences, Modena, Italy. Electronic address: gtosi@unimore.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH